For three years Legal Alliance lawyers have been defending the interests in a client primary claim dispute on the admission of violation of intellectual property rights for an invention, and partial cancellation of an Order of the Ministry of Health of Ukraine on the registration of medicine of the opponent, and counterclaim on revocation of the patent of Ukraine for medicine.
As a result of properly developed defense and proof tactics in this dispute, after a number of expertise in response to client`s order, we refuted opponent`s argument with regard to the patent not meeting two patentability requirements at the same time (inventive step and novelty), also, we proved that in its medicine the opponent used every formula primary claim features of the invention or equivalent features.
It should be mentioned that less substances were used in one of the features of the opponent’s medicine than the invention formula required. The opponent used this fact as a leverage when contesting the use of the invention. Yet, Legal Alliance lawyers proved the equivalency of features by receiving a separate conclusion from an expert where the issue of the equivalence of the features mentioned was researched.
The chosen vector led to the court decision to meet the primary claim fully and completely and to deny meeting counter claims.
Client`s interests were defended by company`s Advisor Vitalii Savchuk, as well as lawyer and attorney Nataliia Abramovych.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.